Theranostics in prostate cancer management: Current strategies and real-world data
21 Mar 2025
bởiElaine Tan
Earlier use of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA)–radioligand therapy (RLT) in combination with chemotherapy is shaping the future of prostate cancer management, according to Dr Yu-Yi Huang of the Department of Nuclear Medicine, Koo-Foundation Sun Yat-Sen Cancer Center (SYSCC), Taiwan, at Uro-Oncology Asia 2025.